<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524221</url>
  </required_header>
  <id_info>
    <org_study_id>57613</org_study_id>
    <secondary_id>PTG-100-05-CeD</secondary_id>
    <nct_id>NCT04524221</nct_id>
  </id_info>
  <brief_title>PTG-100 for Patients With Celiac Disease</brief_title>
  <official_title>A Phase 1b Study of PTG-100 in Patients With Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nielsen Fernandez-Becker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Protagonist Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to learn whether or not the drug PTG-100 can reduce or prevent&#xD;
      inflammatory injury to the small intestine that occurs when people with celiac disease eat&#xD;
      food products containing gluten.&#xD;
&#xD;
      This is a clinical research study to determine the safety and efficacy of PTG-100 in&#xD;
      preventing gluten-induced inflammatory injury to the small intestine in patients with celiac&#xD;
      disease. 30 patients will receive either placebo (fake drug) or PTG-100 (real drug) in&#xD;
      capsule form twice daily for 42 days. They will also receive a gluten challenge twice daily&#xD;
      in the form of a cookie or equivalent. An upper gastrointestinal endoscopy and exam including&#xD;
      small bowel mucosa biopsy will be performed at the start of the treatment period and again at&#xD;
      the end. Blood samples will be routinely taken to evaluate safety and the drug's mechanism of&#xD;
      action throughout the study, and symptoms will be recorded using the celiac symptoms index&#xD;
      (CSI) survey.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in villous height-to crypt ratio</measure>
    <time_frame>42 days</time_frame>
    <description>Percentage change from baseline to Week 6 in villous height-to crypt depth (Vh:Cd) ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in celiac disease antibodies</measure>
    <time_frame>42 days</time_frame>
    <description>Changes in anti-tTG antibodies from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in celiac disease antibodies</measure>
    <time_frame>42 days</time_frame>
    <description>Changes in anti-DGP antibodies from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3- positive intraepithelial lymphocyte density</measure>
    <time_frame>42 days</time_frame>
    <description>CD3- positive intraepithelial lymphocyte density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Celiac symptom index (CSI)</measure>
    <time_frame>42 days</time_frame>
    <description>Changes in validated celiac symptom index (CSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of immune modulators underlying mechanism of action in celiac disease.</measure>
    <time_frame>42 days</time_frame>
    <description>Identification of immune cell populations targeted by PTG-100 to better understand mechanism of action in celiac disease in both blood and tissue temporally following exposure to drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>PTG-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTG-100</intervention_name>
    <description>PTG-100, 600mg taken twice daily in capsule form for 42 days</description>
    <arm_group_label>PTG-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken twice daily in capsule form for 42 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of celiac disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active GI disease or history of clinically significant diseases&#xD;
&#xD;
          -  Diagnosis of Crohn's disease or ulcerative colitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nielsen Q Fernandez-Becker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aubrey Adiao, BS</last_name>
    <phone>(650) 721-3177</phone>
    <email>aadiao@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Nielsen Fernandez-Becker</investigator_full_name>
    <investigator_title>Clinical Associate Professor, Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

